ACCELERATING PERSONALIZED / PRECISION MEDICINE
Founded in 2006, Population Bio (PB) discovers causative genetic biomarkers to:
- Develop and market DNA-based diagnostic tests for pre-symptomatic early detection of disease.
- Enable pharmaceutical companies to develop companion diagnostics and novel targeted drugs with greater efficacy and safety.
- Transform how physicians diagnose and manage disease in their patients.
Our core technology rationally interprets the vast spectrum of variation in human genomes to uncover the genetic components of complex diseases such as Autism, Parkinson’s, Alzheimer’s, and Endometriosis.
Population Bio, the CNV company, discovers disease genes via its CNV Beacon® method to accelerate the delivery of precision medicine diagnostic and therapeutic products to enable safe, low-cost, and more effective healthcare for patients.